Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 2260043
TL;DR
Results demonstrate that AZD6563, at reduced doses, matches the cellular immunogenicity of BNT162b2 while enhancing B cell cross-reactivity and TCR diversity in older adults, supporting its potential as a next-generation COVID-19 vaccine candidate.
Abstract
mRNA-encoded virus-like particles (VLPs) are an emerging advancement in vaccine technology, enabling the self-assembly of viral antigens into structures that closely resemble native viruses. This innovative approach to conventional mRNA vaccination may boost vaccine-induced adaptive immune responses and allow for reduced dosing. To evaluate this technology, we developed AZD6563, an mRNA VLP vaccine targeting the COVID-19 XBB1.5 spike variant. The phase 1 clinical study ARTEMIS-C was conducted to assess cellular immunogenicity in adults aged 18—64 years and ≥65 years following administration of AZD6563 (5 µg or 10 µg) or the licensed BNT162b2 XBB.1.5 mRNA vaccine (30 µg). AZD6563 drove spike-specific CD4+ and CD8+ T cell responses comparable to those elicited by higher dose of BNT162b2. Functional analysis of these cells revealed similar cytokine production profiles across groups; however, the 10µg dose of AZD6563 led to higher TCR diversity within the ≥65-year cohort. Notably, expansion of spike-specific B cells was most pronounced in the AZD6563 10µg group, with marked increases in cross-reactive XBB.1.5 spike-specific B cells that also recognized Omicron BA.4/5 and ancestral SARS-CoV-2 variants. Collectively, these results demonstrate that AZD6563, at reduced doses, matches the cellular immunogenicity of BNT162b2 while enhancing B cell cross-reactivity and TCR diversity in older adults, supporting its potential as a next-generation COVID-19 vaccine candidate. n/a Vaccines and Immunotherapy (VAC)